Report

  1. Home
  2. Discounted reports

Vaccines Market By Technology Type (Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Others), By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP), Polio, Hepatitis, Other Indications), By End User (Pediatric, Adults, Travelers): Global Opportunity Analysis and Industry Forecast, 2024-2035

Market Report I 2024-04-01 I 350 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

The vaccine market was valued at $43.2 billion in 2023 and is projected to reach $90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine. The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.
Key Benefits for Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology Type
- Inactivated Vaccines
- Toxoid Vaccines
- Others
- Recombinant and Conjugate Vaccines
- Live Attenuated Vaccines
By Indication
- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella
- Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DTP)
- Polio
- Hepatitis
- Other Indications
By End User
- Pediatric
- Adults
- Travelers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- CSL Limited
- Emergent Bi
o Solutions Inc.
- GlaxoSmithKline Plc.
- Merck & Co., Inc.
- Pfizer
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Bavarian Nordic
- Zhi Fei Biological
- Bharat Biotech

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Recombinant and Conjugate Vaccines
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Live Attenuated Vaccines
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Inactivated Vaccines
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Toxoid Vaccines
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: VACCINES MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Pneumococcal Disease
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Influenza
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Human Papilloma Virus
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Meningococcal Disease
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Rotavirus
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Varicella
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Measles, Mumps, and Rubella
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
5.9. Diphtheria, Pertussis, and Tetanus (DTP)
5.9.1. Key market trends, growth factors and opportunities
5.9.2. Market size and forecast, by region
5.9.3. Market share analysis by country
5.10. Polio
5.10.1. Key market trends, growth factors and opportunities
5.10.2. Market size and forecast, by region
5.10.3. Market share analysis by country
5.11. Hepatitis
5.11.1. Key market trends, growth factors and opportunities
5.11.2. Market size and forecast, by region
5.11.3. Market share analysis by country
5.12. Other Indications
5.12.1. Key market trends, growth factors and opportunities
5.12.2. Market size and forecast, by region
5.12.3. Market share analysis by country
CHAPTER 6: VACCINES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Adults
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Travelers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: VACCINES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Technology Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Technology Type
7.2.5.1.2. Market size and forecast, by Indication
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Technology Type
7.2.5.2.2. Market size and forecast, by Indication
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Technology Type
7.2.5.3.2. Market size and forecast, by Indication
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Technology Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Technology Type
7.3.5.1.2. Market size and forecast, by Indication
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.3.2. Market size and forecast, by Indication
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Technology Type
7.3.5.4.2. Market size and forecast, by Indication
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Technology Type
7.3.5.5.2. Market size and forecast, by Indication
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Technology Type
7.3.5.6.2. Market size and forecast, by Indication
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Technology Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Technology Type
7.4.5.1.2. Market size and forecast, by Indication
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Technology Type
7.4.5.2.2. Market size and forecast, by Indication
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Technology Type
7.4.5.3.2. Market size and forecast, by Indication
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Technology Type
7.4.5.4.2. Market size and forecast, by Indication
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Technology Type
7.4.5.5.2. Market size and forecast, by Indication
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Technology Type
7.4.5.6.2. Market size and forecast, by Indication
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Technology Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Technology Type
7.5.5.1.2. Market size and forecast, by Indication
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Technology Type
7.5.5.2.2. Market size and forecast, by Indication
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Technology Type
7.5.5.3.2. Market size and forecast, by Indication
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Technology Type
7.5.5.4.2. Market size and forecast, by Indication
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. CSL Limited
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Emergent Bio Solutions Inc.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. GlaxoSmithKline Plc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Merck & Co., Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Pfizer
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Sanofi
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Serum Institute of India Pvt. Ltd.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Bavarian Nordic
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Zhi Fei Biological
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Bharat Biotech
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 02. VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 03. VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 04. VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 05. VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2023-2035 ($MILLION)
TABLE 06. VACCINES MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 07. GLOBAL VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 08. VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2023-2035 ($MILLION)
TABLE 09. VACCINES MARKET FOR INFLUENZA, BY REGION, 2023-2035 ($MILLION)
TABLE 10. VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2023-2035 ($MILLION)
TABLE 11. VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2023-2035 ($MILLION)
TABLE 12. VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2023-2035 ($MILLION)
TABLE 13. VACCINES MARKET FOR VARICELLA, BY REGION, 2023-2035 ($MILLION)
TABLE 14. VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY REGION, 2023-2035 ($MILLION)
TABLE 15. VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY REGION, 2023-2035 ($MILLION)
TABLE 16. VACCINES MARKET FOR POLIO, BY REGION, 2023-2035 ($MILLION)
TABLE 17. VACCINES MARKET FOR HEPATITIS, BY REGION, 2023-2035 ($MILLION)
TABLE 18. VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2035 ($MILLION)
TABLE 19. GLOBAL VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 20. VACCINES MARKET FOR PEDIATRIC, BY REGION, 2023-2035 ($MILLION)
TABLE 21. VACCINES MARKET FOR ADULTS, BY REGION, 2023-2035 ($MILLION)
TABLE 22. VACCINES MARKET FOR TRAVELERS, BY REGION, 2023-2035 ($MILLION)
TABLE 23. VACCINES MARKET, BY REGION, 2023-2035 ($MILLION)
TABLE 24. NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 25. NORTH AMERICA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 26. NORTH AMERICA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 27. NORTH AMERICA VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 28. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 29. U.S. VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 30. U.S. VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 31. CANADA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 32. CANADA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 33. CANADA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 34. MEXICO VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 35. MEXICO VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 36. MEXICO VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 37. EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 38. EUROPE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 39. EUROPE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 40. EUROPE VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 41. GERMANY VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 42. GERMANY VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 43. GERMANY VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 44. FRANCE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 45. FRANCE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 46. FRANCE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 47. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 48. UK VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 49. UK VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 50. ITALY VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 51. ITALY VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 52. ITALY VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 53. SPAIN VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 54. SPAIN VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 55. SPAIN VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 56. REST OF EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 57. REST OF EUROPE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 58. REST OF EUROPE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 59. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 60. ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 61. ASIA-PACIFIC VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 62. ASIA-PACIFIC VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 63. JAPAN VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 64. JAPAN VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 65. JAPAN VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 66. CHINA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 67. CHINA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 68. CHINA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 69. INDIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 70. INDIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 71. INDIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 72. AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 73. AUSTRALIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 74. AUSTRALIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 75. SOUTH KOREA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 76. SOUTH KOREA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 77. SOUTH KOREA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 81. LAMEA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 82. LAMEA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 83. LAMEA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 84. LAMEA VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 85. BRAZIL VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 86. BRAZIL VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 87. BRAZIL VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 88. SAUDI ARABIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 89. SAUDI ARABIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 90. SAUDI ARABIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 91. SOUTH AFRICA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 92. SOUTH AFRICA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 93. SOUTH AFRICA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 94. REST OF LAMEA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
TABLE 95. REST OF LAMEA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 96. REST OF LAMEA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 97. CSL LIMITED: KEY EXECUTIVES
TABLE 98. CSL LIMITED: COMPANY SNAPSHOT
TABLE 99. CSL LIMITED: PRODUCT SEGMENTS
TABLE 100. CSL LIMITED: SERVICE SEGMENTS
TABLE 101. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 102. CSL LIMITED: KEY STRATEGIES
TABLE 103. EMERGENT BIO SOLUTIONS INC.: KEY EXECUTIVES
TABLE 104. EMERGENT BIO SOLUTIONS INC.: COMPANY SNAPSHOT
TABLE 105. EMERGENT BIO SOLUTIONS INC.: PRODUCT SEGMENTS
TABLE 106. EMERGENT BIO SOLUTIONS INC.: SERVICE SEGMENTS
TABLE 107. EMERGENT BIO SOLUTIONS INC.: PRODUCT PORTFOLIO
TABLE 108. EMERGENT BIO SOLUTIONS INC.: KEY STRATEGIES
TABLE 109. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 110. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 111. GLAXOSMITHKLINE PLC.: PRODUCT SEGMENTS
TABLE 112. GLAXOSMITHKLINE PLC.: SERVICE SEGMENTS
TABLE 113. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 114. GLAXOSMITHKLINE PLC.: KEY STRATEGIES
TABLE 115. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 116. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 117. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 118. MERCK & CO., INC.: SERVICE SEGMENTS
TABLE 119. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 120. MERCK & CO., INC.: KEY STRATEGIES
TABLE 121. PFIZER: KEY EXECUTIVES
TABLE 122. PFIZER: COMPANY SNAPSHOT
TABLE 123. PFIZER: PRODUCT SEGMENTS
TABLE 124. PFIZER: SERVICE SEGMENTS
TABLE 125. PFIZER: PRODUCT PORTFOLIO
TABLE 126. PFIZER: KEY STRATEGIES
TABLE 127. SANOFI: KEY EXECUTIVES
TABLE 128. SANOFI: COMPANY SNAPSHOT
TABLE 129. SANOFI: PRODUCT SEGMENTS
TABLE 130. SANOFI: SERVICE SEGMENTS
TABLE 131. SANOFI: PRODUCT PORTFOLIO
TABLE 132. SANOFI: KEY STRATEGIES
TABLE 133. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
TABLE 134. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 135. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS
TABLE 136. SERUM INSTITUTE OF INDIA PVT. LTD.: SERVICE SEGMENTS
TABLE 137. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 138. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIES
TABLE 139. BAVARIAN NORDIC: KEY EXECUTIVES
TABLE 140. BAVARIAN NORDIC: COMPANY SNAPSHOT
TABLE 141. BAVARIAN NORDIC: PRODUCT SEGMENTS
TABLE 142. BAVARIAN NORDIC: SERVICE SEGMENTS
TABLE 143. BAVARIAN NORDIC: PRODUCT PORTFOLIO
TABLE 144. BAVARIAN NORDIC: KEY STRATEGIES
TABLE 145. ZHI FEI BIOLOGICAL: KEY EXECUTIVES
TABLE 146. ZHI FEI BIOLOGICAL: COMPANY SNAPSHOT
TABLE 147. ZHI FEI BIOLOGICAL: PRODUCT SEGMENTS
TABLE 148. ZHI FEI BIOLOGICAL: SERVICE SEGMENTS
TABLE 149. ZHI FEI BIOLOGICAL: PRODUCT PORTFOLIO
TABLE 150. ZHI FEI BIOLOGICAL: KEY STRATEGIES
TABLE 151. BHARAT BIOTECH: KEY EXECUTIVES
TABLE 152. BHARAT BIOTECH: COMPANY SNAPSHOT
TABLE 153. BHARAT BIOTECH: PRODUCT SEGMENTS
TABLE 154. BHARAT BIOTECH: SERVICE SEGMENTS
TABLE 155. BHARAT BIOTECH: PRODUCT PORTFOLIO
TABLE 156. BHARAT BIOTECH: KEY STRATEGIES

LIST OF FIGURES
FIGURE 01. VACCINES MARKET, 2023-2035
FIGURE 02. SEGMENTATION OF VACCINES MARKET,2023-2035
FIGURE 03. TOP IMPACTING FACTORS IN VACCINES MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN VACCINES MARKET (2024-2035)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. VACCINES MARKET, BY TECHNOLOGY TYPE, 2023 AND 2035(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY 2023 AND 2035(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR OTHERS, BY COUNTRY 2023 AND 2035(%)
FIGURE 17. VACCINES MARKET, BY INDICATION, 2023 AND 2035(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY 2023 AND 2035(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR INFLUENZA, BY COUNTRY 2023 AND 2035(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY 2023 AND 2035(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY 2023 AND 2035(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY 2023 AND 2035(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR VARICELLA, BY COUNTRY 2023 AND 2035(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY 2023 AND 2035(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY 2023 AND 2035(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR POLIO, BY COUNTRY 2023 AND 2035(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR HEPATITIS, BY COUNTRY 2023 AND 2035(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY 2023 AND 2035(%)
FIGURE 29. VACCINES MARKET, BY END USER, 2023 AND 2035(%)
FIGURE 30. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR PEDIATRIC, BY COUNTRY 2023 AND 2035(%)
FIGURE 31. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR ADULTS, BY COUNTRY 2023 AND 2035(%)
FIGURE 32. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR TRAVELERS, BY COUNTRY 2023 AND 2035(%)
FIGURE 33. VACCINES MARKET BY REGION, 2023 AND 2035(%)
FIGURE 34. U.S. VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 35. CANADA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 36. MEXICO VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 37. GERMANY VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 38. FRANCE VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 39. UK VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 40. ITALY VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 41. SPAIN VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 42. REST OF EUROPE VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 43. JAPAN VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 44. CHINA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 45. INDIA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 46. AUSTRALIA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 47. SOUTH KOREA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 48. REST OF ASIA-PACIFIC VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 49. BRAZIL VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 50. SAUDI ARABIA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 51. SOUTH AFRICA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 52. REST OF LAMEA VACCINES MARKET, 2023-2035 ($MILLION)
FIGURE 53. TOP WINNING STRATEGIES, BY YEAR
FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 56. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 57. COMPETITIVE DASHBOARD
FIGURE 58. COMPETITIVE HEATMAP: VACCINES MARKET
FIGURE 59. TOP PLAYER POSITIONING, 2023

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3840.00 $3456.00
  • $6090.00 $5481.00
  • $10500.00 $9450.00
  • ADD TO BASKET
  • BUY NOW